This study aimed to design a compound with folic acid (FAH 2) and vanadyl (IV) for use in the treatment of diabetes.
A novel vanadyl (IV) FAH 2 complex was synthesized and characterized [(FA 2−)(VO 2+)]⋅3H 2O. The speculated structure of this folate complex was determined using physicochemical techniques including microanalytical analysis, conductivity studies, spectroscopic examination, magnetic measurements, thermogravimetric analyses, and morphological X-ray powder diffraction, and scanning and transmission electron microscopies. The anti-diabetic therapeutic potential of the complexes was tested in a 30-day streptozotocin-induced diabetes rat model.
The conductivity test of the complex implied electrolyte behavior. The spectroscopic assessments of the isolated dark yellow solid complex revealed that FAH 2 acts as a bidentate ligand. The coordination process with two vanadyl (IV) ions occurred through the deprotonation of both carboxyl groups of FAH 2 in a regular square pyramid arrangement at a 2(FA) 2−: 2(VO) 2+ molar ratio. XRD, SEM, and TEM analyses revealed the complex crystalline nature of the complex. Treating diabetic rats with vanadyl (IV) FAH 2 complex significantly improved many biological parameters relevant to diabetes pathology with minimal toxicity.